47 results about "Endothelial Growth Factor Receptor" patented technology

The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and / or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and / or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and / or VEGFr gene expression and / or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and / or VEGFr expression or activity.

Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I)and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).

The present invention is directed to methods of treating an inflammatory condition in a patient. This method includes providing a therapeutic agent that is a vascular endothelial growth factor receptor-3 (VEGFR-3) agonist or a nucleic acid molecule encoding a VEGFR-3 agonist. The present invention is further directed to pharmaceutical compositions and therapeutic systems for treating an inflammatory condition.

The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1+ bone marrow-derived cells. Metastases in a cancer patient can be monitored by evaluating a patient sample for detection and quantification of vascular endothelial growth factor receptor 1+ bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1+ bone marrow-derived cells to prior levels.

The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and / or nails, which are associated with administration of one or more vascular endothelial growth factor receptor inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.

The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.

The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor receptor (VEGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.

A polypeptide inhibiting binding between vascular endothelial growth factor receptor-2 and a vascular endothelial growth factor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.

The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1+ bone marrow-derived cells. Metastases in a cancer patient can be monitored by evaluating a patient sample for detection and quantification of vascular endothelial growth factor receptor 1+ bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1+ bone marrow-derived cells to prior levels.

Aiming at the prior art, the invention aims to provide an anticancer composition based on an anti-angiogenesis medicine. The anticancer composition comprises a vascular endothelial growth factor receptor protein kinase inhibition medicine, namely a VEGFR inhibition medicine; and furthermore, according to the characteristic of a molecular passageway, a targeted medicine deoxyverrucosidin and a medically accepted carrier or excipient thereof are selected to be combined with the VEGFR inhibition medicine and a medically accepted carrier or excipient thereof, so that the problem of medicine resistance of the VEGFR inhibition medicine is fundamentally solved; and the effect of treating cancers is greatly enhanced.

The related chalketoxime shown as the formula (1) is prepared by heating and reflux reacting the 2', 4'-dihydroxy -6'-methoxyl-3', 5'-dimethylchalcone and hydroxylamine hydrochloride in pyridine, which has well solvability, fit to direct inject for drug, restrains obviously all of the activity of blood vessel endothelium growth factor receptor, HER2 receptor and Tyr kinase as PDGFR receptor, the external growth of cells for breast cancer and liver cancer, and the phosphorylation of KDR in ECV304 cell, HER2 in MDA-MB-453 cell and PDGFR receptor in C6 cell, and benefit to treat tumor.

The invention relates to the field of medicines and particularly relates to polypeptide for inhibiting vascular endothelial growth factor receptors 2 tyrosine kinase and preventing and treating the rheumatoid arthritis. After the polypeptide is modified with polyethylene glycol and the sequence of the polypeptide is Mpeg-SC10k-Val-Cys-CyS-Ser-Thr-Arg-Glu which is an entirely-new sequence. The polypeptide can be used for treating the rheumatoid arthritis and has potential new-medicine development value.

The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as active ingredient; uses in the preparation of vascular endothelial growth factor receptor tyrosine kinase inhibitors, and uses in the preparation of medicament for the treatment and / or prevention of cancer.

The invention relates to a recombinant human vascular endothelial factor receptor-antibody fusion protein preparation and its preparation. Specifically, the pharmaceutical combination preparation of the present invention comprises recombinant fusion protein, buffer, stabilizer, surfactant and sterile water for injection. The pharmaceutical combination preparation of the present invention can effectively inhibit side reactions such as aggregation and precipitation, hydrolysis, oxidation, and deamidation of the fusion protein, and can effectively improve the stability of the product under pressurized (high temperature, strong light irradiation, freeze-thaw, etc.), accelerated, and long-term refrigerated conditions. The stability can improve the safety of clinical use.